tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Gliosis D005911 6 associated lipids
Kidney Tubular Necrosis, Acute D007683 3 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Hallucinations D006212 4 associated lipids
Sleep Wake Disorders D012893 7 associated lipids
Rosacea D012393 13 associated lipids
Pericarditis D010493 6 associated lipids
Hyperpigmentation D017495 11 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Long QT Syndrome D008133 10 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Mycoses D009181 18 associated lipids
Liver Failure D017093 5 associated lipids
Epilepsy, Temporal Lobe D004833 4 associated lipids
Retinoblastoma D012175 12 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Gastroenteritis D005759 4 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
Inappropriate ADH Syndrome D007177 4 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Lymphoma, T-Cell D016399 11 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Pityriasis D010915 3 associated lipids
Hand Dermatoses D006229 5 associated lipids
Postoperative Hemorrhage D019106 7 associated lipids
Liver Abscess D008100 6 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Foot Dermatoses D005533 3 associated lipids
Anus Diseases D001004 3 associated lipids
Endomyocardial Fibrosis D004719 4 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Herpesviridae Infections D006566 4 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Pouchitis D019449 3 associated lipids
Granuloma, Giant Cell D006101 7 associated lipids
Epstein-Barr Virus Infections D020031 3 associated lipids
Labyrinthitis D007762 2 associated lipids
Foot Deformities, Acquired D005531 2 associated lipids
Dermatomyositis D003882 2 associated lipids
Dementia, Vascular D015140 7 associated lipids
Mastocytosis D008415 5 associated lipids
Molluscum Contagiosum D008976 2 associated lipids
Paresis D010291 2 associated lipids
Intracranial Hypertension D019586 4 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Chronic Disease D002908 7 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Vitiligo D014820 2 associated lipids
Hemophilia B D002836 3 associated lipids
Myasthenia Gravis D009157 5 associated lipids
Hyperkalemia D006947 3 associated lipids
Intracranial Thrombosis D020767 2 associated lipids
Pemphigus, Benign Familial D016506 3 associated lipids
Skin Diseases, Vesiculobullous D012872 5 associated lipids
Prurigo D011536 4 associated lipids
Hepatitis, Viral, Animal D006524 4 associated lipids
Cryptococcosis D003453 3 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Castleman Disease D005871 3 associated lipids
Wounds, Stab D014951 3 associated lipids
Keratosis, Actinic D055623 3 associated lipids
Toxocariasis D014120 3 associated lipids
Fistula D005402 8 associated lipids
Confusion D003221 4 associated lipids
Encephalitis, Viral D018792 3 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Hyperuricemia D033461 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Viremia D014766 4 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Parotitis D010309 4 associated lipids
Tuberous Sclerosis D014402 2 associated lipids
Ocular Motility Disorders D015835 2 associated lipids
Pain, Intractable D010148 4 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Perceptual Disorders D010468 3 associated lipids
Polyneuropathies D011115 3 associated lipids
Heart Injuries D006335 6 associated lipids
Hearing Loss, Noise-Induced D006317 4 associated lipids
Exanthema D005076 11 associated lipids
Bronchiolitis D001988 6 associated lipids
Reflex Sympathetic Dystrophy D012019 4 associated lipids
Kartagener Syndrome D007619 2 associated lipids
Earache D004433 2 associated lipids
Delayed Graft Function D051799 2 associated lipids
Gingival Hyperplasia D005885 3 associated lipids
Intussusception D007443 1 associated lipids
Neoplasms, Second Primary D016609 4 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Apraxias D001072 1 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Venous Insufficiency D014689 2 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Myers SA Update on new immunomodulatory agents. 2000 Adv Dermatol pmid:11094629
Gonin JM Maintenance immunosuppression: new agents and persistent dilemmas. 2000 Adv Ren Replace Ther pmid:10782729
Ginocchio L et al. Refractory Ulcerated Necrobiosis Lipoidica: Closure of a Difficult Wound with Topical Tacrolimus. 2017 Adv Skin Wound Care pmid:28914682
Balal M et al. Effects of cyclosporine and tacrolimus on maintenance therapy after renal transplantation. 2004 May-Jun Adv Ther pmid:15509135
Diao H et al. Comparison of tacrolimus, fluorometholone, and saline in mild-to-moderate contact lens-induced papillary conjunctivitis. 2012 Adv Ther pmid:22821643
Hon KL et al. Assessing itch in children with atopic dermatitis treated with tacrolimus: objective versus subjective assessment. 2007 Jan-Feb Adv Ther pmid:17526458
Mancilla UE et al. Primary immunosuppression with tacrolimus in renal transplantation: a multicenter, open-label study. 1999 Sep-Oct Adv Ther pmid:10915396
Lionetti P et al. Mucosal adaptation and destruction in response to lamina propria T cell activation in explants of human fetal intestine. 1995 Adv. Exp. Med. Biol. pmid:8525974
Mori A et al. Enhanced production and gene expression of IL-5 in bronchial asthma. Possible management of atopic diseases with IL-5 specific gene transcription inhibitor. 1996 Adv. Exp. Med. Biol. pmid:9095279
Shahidi M Thrombosis and von Willebrand Factor. 2017 Adv. Exp. Med. Biol. pmid:27628010
Clemann N and Bechter R Effects of rapamycin and FK 506 on rat Sertoli cells in vitro. 1998 Adv. Exp. Med. Biol. pmid:10026935
Thomson AW and Bonham CA Inhibition of T lymphocyte activation and apoptotic cell death by cyclosporin A and tacrolimus (FK506). Its relevance to therapy of HIV infection. 1995 Adv. Exp. Med. Biol. pmid:7572394
Abramowicz D et al. Immunosuppressive strategies in renal transplantation at the beginning of the third millennium. 2000 Adv. Nephrol. Necker Hosp. pmid:11068631
Li PK et al. The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506. 1990 Adverse Drug React Acute Poisoning Rev pmid:1703724
Doren EL and Aya-ay ML Pyoderma gangrenosum following breast reduction: treatment with topical tacrolimus and steroids. 2014 Aesthet Surg J pmid:24448967
Bolton C The efficacy of cyclosporin A, FK-506 and prednisolone to modify the adoptive transfer of experimental allergic encephalomyelitis (EAE). 1992 Agents Actions pmid:1380765
Griffiths RJ et al. Characterisation of passively transferred antigen arthritis induced by methylated bovine serum albumin in the rat: effect of FK 506 on arthritis development. 1992 Agents Actions pmid:1384284
Martín-Cano FE et al. mTOR pathway and Ca²⁺ stores mobilization in aged smooth muscle cells. 2013 Aging (Albany NY) pmid:23661091
Sekigawa I et al. FK506 can inhibit apoptotic cell death induced by the HIV-1 envelope glycoprotein gp120. 1994 AIDS pmid:7531458
Antonini TM et al. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation. 2015 AIDS pmid:25387314
Florio G et al. The immunoglobulin superantigen-binding site of HIV-1 gp120 activates human basophils. 2000 AIDS pmid:10853974
Nowak P et al. Follow-up of antiretroviral treatment in liver transplant recipients with primary and chronic HIV type 1 infection. 2003 AIDS Res. Hum. Retroviruses pmid:12581512
Sklar EM Post-transplant neurotoxicity: what role do calcineurin inhibitors actually play? 2006 AJNR Am J Neuroradiol pmid:16971594
Bargalló N et al. Cortical laminar necrosis caused by immunosuppressive therapy and chemotherapy. 2000 AJNR Am J Neuroradiol pmid:10730638
Bartynski WS et al. Etiology of cortical and white matter lesions in cyclosporin-A and FK-506 neurotoxicity. 2001 Nov-Dec AJNR Am J Neuroradiol pmid:11733324
Bartynski WS et al. Pretransplantation conditioning influence on the occurrence of cyclosporine or FK-506 neurotoxicity in allogeneic bone marrow transplantation. 2004 AJNR Am J Neuroradiol pmid:14970028
Bartynski WS et al. Posterior reversible encephalopathy syndrome after solid organ transplantation. 2008 AJNR Am J Neuroradiol pmid:18272559
Schuuring J et al. Severe tacrolimus leukoencephalopathy after liver transplantation. 2003 Nov-Dec AJNR Am J Neuroradiol pmid:14625238
Oliverio PJ et al. Reversible tacrolimus-induced neurotoxicity isolated to the brain stem. 2000 AJNR Am J Neuroradiol pmid:10954277
Appignani BA et al. Neuroimaging findings in patients on immunosuppressive therapy: experience with tacrolimus toxicity. 1996 AJR Am J Roentgenol pmid:8623651
Landy J and Hart AL Commentary: short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis. 2013 Aliment. Pharmacol. Ther. pmid:23336680
Hirai F et al. Letter: short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis. 2013 Aliment. Pharmacol. Ther. pmid:23336690
Schmidt KJ et al. Letter: short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - authors' reply. 2013 Aliment. Pharmacol. Ther. pmid:23336691
Baumgart DC et al. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. 2003 Aliment. Pharmacol. Ther. pmid:12755840
Srinivas NR Letter: sublingual dosing of tacrolimus in transplant patients-interesting concept to overcome first pass effects. 2017 Aliment. Pharmacol. Ther. pmid:28589592
Benítez C et al. Letter: sublingual dosing of tacrolimus in transplant patients-interesting concept to overcome first pass effects. Authors' reply. 2017 Aliment. Pharmacol. Ther. pmid:28589580
Yamamoto T et al. Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study. 2016 Aliment. Pharmacol. Ther. pmid:26762838
Travis S Review article: saving the colon in severe colitis - the case for medical therapy. 2006 Aliment. Pharmacol. Ther. pmid:16961749
Schmidt KJ et al. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients. 2013 Aliment. Pharmacol. Ther. pmid:23121200
McSharry K et al. Systematic review: the role of tacrolimus in the management of Crohn's disease. 2011 Aliment. Pharmacol. Ther. pmid:21999607
Yamamoto S et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. 2008 Aliment. Pharmacol. Ther. pmid:18549460
O'Leary JG Editorial: tacrolimus-how low can you go? 2017 Aliment. Pharmacol. Ther. pmid:28589579
Firpi RJ et al. Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent. 2004 Aliment. Pharmacol. Ther. pmid:15113371
Herrlinger KR et al. Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. 2010 Aliment. Pharmacol. Ther. pmid:20175769
Solari S et al. Sublingual tacrolimus administration provides similar drug exposure to per-oral route employing lower doses in liver transplantation: a pilot study. 2017 Aliment. Pharmacol. Ther. pmid:28261844
Hisanaga Y et al. Implication of nitric oxide synthase activity in the genesis of water immersion stress-induced gastric lesions in rats: the protective effects of FK506. 1996 Aliment. Pharmacol. Ther. pmid:8971291
Nakase H et al. Tacrolimus suppresses IL-12/IL23 p40 in Crohn's disease and heals fistulae refractory to anti-TNF-α therapy. 2011 Aliment. Pharmacol. Ther. pmid:21434949
Nakase H et al. Tacrolimus: rescue therapy or experimental drug for severe ulcerative colitis? 2011 Aliment. Pharmacol. Ther. pmid:21198700
Hoshino H et al. Effects of FK506 on an experimental model of colitis in rats. 1995 Aliment. Pharmacol. Ther. pmid:7544633
Mehta SJ et al. Review article: strategies for the management of chronic unremitting ulcerative colitis. 2013 Aliment. Pharmacol. Ther. pmid:23718288